<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03453112</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-01535BA0-01</org_study_id>
    <nct_id>NCT03453112</nct_id>
  </id_info>
  <brief_title>Foster 100/6 mg NEXThaler Versus Foster 100/6mg Pressurized Metered-dose Inhaler (pMDI) in Patients With Controlled Asthma.</brief_title>
  <acronym>FORTUNE</acronym>
  <official_title>A 12-week, Multicenter, Randomized, Double-blind, Double-dummy, 2-arm Parallel Group Study Comparing the Efficacy and Safety of Foster 100/6mg NEXThaler, 2 Inhalations b.i.d, Versus Foster 100/6mg pMDI, 2 Puffs b.i.d in Patients With Controlled Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the non-inferiority of Foster 100/6mg NEXThaler
      versus Foster 100/6mg pMDI in terms of pulmonary function in asthmatic patients, as well as
      the effect of the test treatments in terms of additional lung function parameters and
      clinical outcome measures. The purpose is also to assess the safety and tolerability.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2017</start_date>
  <completion_date type="Anticipated">March 19, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 19, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Demonstration of non-inferiority of Foster 100/6mg NEXThaler versus Foster 100/6mg pMDI in terms of pulmonary function</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Change from Baseline to the entire treatment period in average pre-dose morning Peek Expiratory flow (PEF)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of the test treatment in terms of additional lung function parameters and clinical outcome measures, and assessement of the safety and tolerability</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Changes in average pre-dose morning Peek Expiratory flow (PEF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of the test treatment in terms of additional lung function parameters and clinical outcome measures, and assessement of the safety and tolerability</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Changes in average pre-dose evening PEF Daily PEF variability Average use fo rescue medication (number of puffs/day) Percentage of rescue-use free days Average total morning asthma symptom scores Average total evening asthma symptom scores Percentage of asthma symptoms-free days Percentage of asthma control days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of the test treatment in terms of additional lung function parameters and clinical outcome measures, and assessement of the safety and tolerability</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Changes from Baseline in pre-dose morning Forced Expiratory Volume (FEV1) and Forced Vital Capacity (FVC) at each clinic visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the effect of the test treatment in terms of additional lung function parameters and clinical outcome measures, and assessement of the safety and tolerability</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Change from Baseline to end of treatment in the Asthma Control Questionnaire (ACQ)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">700</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Foster 100/6mg NEXThaler</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as inhalation powder with a new dry powder inhaler (NEXThaler)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Foster 100/6mg pMDI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as pMDI with Hydrofluoroalkane ( HFA) -134a propellant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Foster 100/6mg NEXThaler</intervention_name>
    <description>Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as inhalation powder with a new dry powder inhaler</description>
    <arm_group_label>Foster 100/6mg NEXThaler</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Foster 100/6mg pMDI</intervention_name>
    <description>Fixed combination of beclomethasone dipropionate 100mg plus formoterol fumarate 6mg per actuation as pMDI with HFA_134a propellant</description>
    <arm_group_label>Foster 100/6mg pMDI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female outpatients, Chinese ethnicity aged &gt;18 years with a clinical diagnosis
             of asthma for a minimum of 6 months prior to visit 1 confirmed by a chest physician
             according to International guidelines updated 2016 Global Initiative Asthma (GINA).

          -  Positive Response to Reversibility Test.

          -  FEV 1 (Forced Expiratory Volume within the first second) &gt;80% of the predicted normal
             value after appropriate washout from bronchodilators.

          -  Patients on previous regular treatment at a stable dose for at least 3 months prior to
             visit 1 with either high daily dose of ICS ( Inhaled Corticosteroids) or medium daily
             dose of ICS

        Exclusion Criteria:

          -  Pregnant or lactating woment

          -  Intermittent asthma or asthma occurring only duting episodic exposure to an allergen
             or a chemical sensitizer

          -  Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) as defined by the current
             Glocal Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines updated 2016

          -  Current smokers, or ex-smokers

          -  Severe asthma exacerbation leading to intake of systemic corticosteroids (&gt; 10 days)
             within 1 month prior to inclusion or moderate/severe asthma exacerbations

          -  Patients treated with monoclonal antibodies

          -  Patients treated with non-potassium sparing diuretics

          -  Patients treated with monoamine oxidase inhibitors and tricyclic antidepressants

          -  Patients who are receiving therapy that could interact with steroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinping MD Zheng</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chiesi Clinical trial info</last_name>
    <phone>+ 39 0521 279 715</phone>
    <email>clinicaltrials_info@chiesi.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jinping Zheng, MD</last_name>
    <phone>+86 20 8333 7750</phone>
    <email>jpzhenggy@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chiesi Clinical Trial site 15663</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>101100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial site 15613</name>
      <address>
        <city>Changsha</city>
        <state>Changsha</state>
        <zip>410015</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi clinical Trial Site 15610</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi clinical Trial site 15656</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial site 15667</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial site 15668</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial site 15607</name>
      <address>
        <city>Zhanjiang</city>
        <state>Guangdong</state>
        <zip>524001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial site 15668</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangzhou</state>
        <zip>511400</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial site 15614</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial site 15643</name>
      <address>
        <city>Changzhou</city>
        <state>Jiangsu</state>
        <zip>213164</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi clinical Trial site 15621</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi clinical Trial site 15619</name>
      <address>
        <city>Nanchang</city>
        <state>Nanchang</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial site 15650</name>
      <address>
        <city>Hohhot</city>
        <state>Neimenggu</state>
        <zip>010017</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi clinical Trial site 15659</name>
      <address>
        <city>Hohhot</city>
        <state>Neimenggu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial site 15625</name>
      <address>
        <city>Taiyuan</city>
        <state>Shan XI Province</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial site 15664</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial site 15633</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial site 15642</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial site 15634</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300350</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial site 15626</name>
      <address>
        <city>Xian</city>
        <state>Xian</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi clinical Trial site 15636</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial site 15638</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi clinical Trial Site 15611</name>
      <address>
        <city>Hebei</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical trial site 15660</name>
      <address>
        <city>Jilin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial site 15628</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial site 15631</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi clinical trial site 15637</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi clinical Trial site 15651</name>
      <address>
        <city>Shenzhen</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi Clinical Trial site 15666</name>
      <address>
        <city>Shenzhen</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chiesi clinical Trial site 15633</name>
      <address>
        <city>Sichuan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2018</study_first_submitted>
  <study_first_submitted_qc>February 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2018</study_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peek Expiratory Flow (PEF) Lung function tests</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

